FF-10101 is under clinical development by Fujifilm and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FF-10101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FF-10101 is under development for the treatment of relapsed or refractory acute myeloid leukemia. It is a small molecule and administered orally. The drug candidate acts by targeting Fms-like tyrosine kinase 3 (FLT3).
Fujifilm designs, manufactures, and markets healthcare solutions, material solutions, document solutions and imaging systems. The company offers document solutions such as office products, office printers, and allied production services and global services. Its major products include color films, color paper and chemicals, photofinishing equipment, electronic imaging and optical devices, TV camera lenses, security lenses, healthcare products, graphic systems, flat panel display materials, recording media and industrial products. Fujifilm also offers equipment and materials for medical systems, cell culture media and reagents, pharmaceuticals, cosmetics, and supplements. The company serves individual consumers and business enterprises. The company has business presence in the Americas, Europe, and Asia-Pacific. Fujifilm is headquartered in Minato-Ku, Tokyo, Japan.
For a complete picture of FF-10101’s drug-specific PTSR and LoA scores, buy the report here.